|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2012. View Article : Google Scholar
|
|
2
|
Wroblewski LE, Peek RM Jr and Wilson KT:
Helicobacter pylori and gastric cancer: Factors that modulate
disease risk. Clin Microbiol Rev. 23:713–739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buckland G, Agudo A, Luján L, Jakszyn P,
Bueno-de-Mesquita HB, Palli D, Boeing H, Carneiro F, Krogh V,
Sacerdote C, et al: Adherence to a Mediterranean diet and risk of
gastric adenocarcinoma within the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort study. Am J
Clin Nutr. 91:381–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu XP, Kawauchi S, Oga A, Suehiro Y,
Tsushimi K, Tsushimi M and Sasaki K: Combined examination of p27
(Kip1), p21 (Waf1/Cip1) and p53 expression allows precise
estimation of prognosis in patients with gastric carcinoma.
Histopathology. 39:603–610. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Moundhri MS, Nirmala V, Al-Hadabi I,
Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS and Grant
C: The prognostic significance of p53, p27 kip1, p21 waf1,
HER-2/neu and Ki67 proteins expression in gastric cancer: A
clinicopathological and immunohistochemical study of 121 Arab
patients. J Surg Oncol. 91:243–252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gamboa-Dominguez A, Seidl S,
Reyes-Gutierrez E, Hermannstädter C, Quintanilla-Martinez L, Busch
R, Höfler H, Fend F and Luber B: Prognostic significance of
p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric
cancer. J Clin Pathol. 60:756–761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alves MK, Ferrasi AC, Lima VP, Ferreira
MV, de Moura Campos Pardini MI and Rabenhorst SH: Inactivation of
COX-2, HMLH1 and CDKN2A gene by promoter methylation in gastric
cancer: Relationship with histological subtype, tumor location and
Helicobacter pylori genotype. Pathobiology. 78:266–276. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang P, Mei J, Zhang N, Tao J, Tian H and
Fu GH: Helicobacter pylori upregulates the expression of p16 (INK4)
in gastric cancer cells. Hepatogastroenterology. 58:846–853.
2011.PubMed/NCBI
|
|
9
|
Begnami MD, Fregnani JH, Brentani H,
Torres C, Costa WL Jr, Montagnini A, Nonogaki S and Soares FA:
Identification of protein expression signatures in gastric
carcinomas using clustering analysis. J Gastroenterol Hepatol.
27:1–384. 2012. View Article : Google Scholar
|
|
10
|
Begnami MD, Fukuda E, Fregnani JH,
Nonogaki S, Montagnini AL, da Costa WL Jr and Soares FA: Prognostic
implications of altered human epidermal growth factor receptors
(HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor
outcome. J Clin Oncol. 29:1–3036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim MS, Lee HW, Im H, Kim BS, Lee MY, Jeon
JY, Yang DH and Lee BH: Predictable factors for lymph node
metastasis in early gastric cancer-analysis of single institutional
experience. J Gastrointest Surg. 15:1783–1788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimada S, Mimata A, Sekine M, Mogushi K,
Akiyama Y, Fukamachi H, Jonkers J, Tanaka H, Eishi Y and Yuasa Y:
Synergistic tumour suppressor activity of E-cadherin and p53 in a
conditional mouse model for metastatic diffuse-type gastric cancer.
Gut. 61:344–353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mattioli E, Vogiatzi P, Sun A, Abbadessa
G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini
G, et al: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2,
p53, p16 (INK4A), p27 (KIP1), p21 (WAF1), Ki-67 expression patterns
in gastric cancer. J Cell Physiol. 210:183–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kasper HU, Schneider-Stock R, Mellin W and
Roessner A: P21 protein expression and ras-oncogene mutations in
gastric carcinoma: Correlation with clinical data. Int J Oncol.
12:69–74. 1998.PubMed/NCBI
|
|
16
|
Teh M and Lee YS: An immunohistochemical
study of ras oncoprotein expression in gastric carcinoma. Cancer.
72:1846–1848. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yasui W, Akama Y, Kuniyasu H, Yokozaki H,
Semba S, Shimamoto F and Tahara E: Expression of cyclin-dependent
kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and
neoplasia of the stomach: Relationship with p53 status and
proliferative activity. J Pathol. 180:122–128. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jang SJ, Park YW, Park MH, Lee JD, Lee YY,
Jung TJ, Kim IS, Choi IY, Ki M, Choi BY and Ahn MJ: Expression of
cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential
prognostic markers for gastric cancer. Eur J Surg Oncol.
25:157–163. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ichinoe M, Mitomi H, Kikuchi S, Tanabe S,
Akino F and Okayasu I: Mucosal high apoptotic activity and low
p21WAF1/CIP1 expression and submucosal low proliferative activity
in superficially spreading early gastric cancers: Comparison with
the penetrating growth type. Pathol Int. 53:81–89. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wen S, So Y, Singh K, Slingerland JM,
Resnick MB, Zhang S, Ruiz V and Moss SF: Promotion of cytoplasmic
mislocalization of p27 by Helicobacter pylori in gastric cancer.
Oncogene. 31:1–1780. 2011.PubMed/NCBI
|
|
21
|
Kim DH, Lee HI, Nam ES, Shin HS, Sohn JH,
Park CH, Yoon DS, Song SY and Park YE: Reduced expression of the
cell-cycle inhibitor p27Kip1 is associated with progression and
lymph node metastasis of gastric carcinoma. Histopathology.
36:245–251. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chesa PG, Rettig WJ, Melamed MR, Old LJ
and Niman HL: Expression of p21ras in normal and malignant human
tissues: Lack of association with proliferation and malignancy.
Proc Natl Acad Sci USA. 84:pp. 3234–3238. 1987; View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mita H, Toyota M, Aoki F, Akashi H,
Maruyama R, Sasaki Y, Suzuki H, Idogawa M, Kashima L, Yanagihara K,
et al: A novel method, digital genome scanning detects KRAS gene
amplification in gastric cancers: Involvement of overexpressed
wild-type KRAS in downstream signaling and cancer cell growth. BMC
Cancer. 9:1982009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kubota E, Kataoka H, Aoyama M, Mizoshita
T, Mori Y, Shimura T, Tanaka M, Sasaki M, Takahashi S, Asai K and
Joh T: Role of ES cell-expressed Ras (ERas) in tumorigenicity of
gastric cancer. Am J Pathol. 177:955–963. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Noda H, Maehara Y, Irie K, Kakeji Y,
Yonemura T and Sugimachi K: Increased proliferative activity caused
by loss of p21 (WAF1/CIP1) expression and its clinical significance
in patients with early-stage gastric carcinoma. Cancer.
94:2107–2112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ogawa M, Maeda K, Onoda N, Chung YS and
Sowa M: Loss of p21WAF1/CIP1 expression correlates with disease
progression in gastric carcinoma. Br J Cancer. 75:1617–1620. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jang SJ, Ahn MJ, Paik SS, Kong G, Keum JS,
Park YW and Lee JD: Expression of cyclin dependent kinase inhibitor
p21WAF1 alone and in combination with p27KIP1 shows prognostic
value in gastric carcinoma. J Korean Med Sci. 13:369–376. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaye PV, Radebold K, Isaacs S and Dent DM:
Expression of p53 and p21waf1/cip1 in astric carcinoma: Lack of
inter-relationship or correlation with prognosis. Eur J Surg Oncol.
26:39–43. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nitti D, Belluco C, Mammano E, Marchet A,
Ambrosi A, Mencarelli R, Segato P and Lise M: Low level of p27
(Kip1) protein expression in gastric adenocarcinoma is associated
with disease progression and poor outcome. J Surg Oncol.
81:167–175. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kishimoto I, Mitomi H, Ohkura Y, Kanazawa
H, Fukui N and Watanabe M: Abnormal expression of p16 (INK4a),
cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in
gastric carcinomas. J Surg Oncol. 98:60–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mattioli E, Vogiatzi P, Sun A, Abbadessa
G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini
G, et al: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2,
p53, p16 (INK4A), p27 (KIP1), p21 (WAF1), Ki-67 expression patterns
in gastric cancer. J Cell Physiol. 210:183–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He XS, Su Q, Chen ZC, He XT, Long ZF, Ling
H and Zhang LR: Expression, deletion and mutation of p16 gene in
human gastric cancer. World J Gastroenterol. 7:515–521. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fenoglio-Preiser Cm, Wang J, Stemmermann
Gn and Noffsinger A: TP53 and Gastric Carcinoma: A Review. Hum
Mutat. 21:258–270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Noda H, Maehara Y, Irie K, Kakeji Y,
Yonemura T and Sugimachi K: Growth pattern and expressions of cell
cycle regulator proteins p53 and p21waf1/cip1 in early gastric
carcinoma. Cancer. 92:1828–1835. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yasui W, Akama Y, Kuniyasu H, Yokozaki H,
Semba S, Shimamoto F and Tahara E: Expression of cyclin-dependent
kinase inhibitor p2lWAFI/CIP1 in non-neoplasic mucosa and neoplasia
of the stomach: Relationship with p53 status and proliferative
activity. J Pathol. 180:122–128. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Czerniak B, Herz F, Gorczyca W and Koss
LG: Expression of ras oncogene p21 protein in early gastric
carcinoma and adjacent gastric epithelia. Cancer. 164:1467–1473.
1989. View Article : Google Scholar
|
|
37
|
Igaki H, Sasaki H, Tachimori Y, Kato H,
Watanabe H, Kimura T, Harada Y, Sugimura T and Terada M: Mutation
frequency of the p16/CDKN2 gene in primary cancers in the upper
digestive tract. Cancer Res. 55:3421–3423. 1995.PubMed/NCBI
|
|
38
|
Ohuchi N, Hand PH, Merlo G, Fujita J,
Mariani-Costantini R, Thor A, Nose M, Callahan R and Schlom J:
Enhanced expression of c-Ha-ras p21 in human stomach
adenocarcinomas defined by immunoassays using monoclonal antibodies
and in situ hybridization. Cancer Res. 47:1413–1420.
1987.PubMed/NCBI
|
